Affiliation:
1. Ural State Medical University of the Ministry of Health of Russia
2. I.Ya. Postovsky Insititute of Organic Synthesis of the Ural Branch of the Russian Academy of Sciences
Abstract
Objective: to prove the possibility of reducing the severity of the course of organ dysfunctions and inflammatory response with the compound L-17 in the model of acute post-manipulation pancreatitis (APMP). Material and methods. The APMP model was made on 40 rats. Animals were divided into control (without treatment) and experimental (with the introduction of the compound L-17) groups of 20 rats. The daily dose of the compound is 40 mg/kg. Results. APMP developed in all animals. In the control group, persistent organ dysfunction and inflammatory response corresponded to a severe course of acute pancreatitis with a mortality rate of 70%. In the experimental group, there was a decrease in the severity of organ dysfunction and inflammatory response, with a decrease in mortality up to 30%. Conclusion. The use of the compound L-17 reduces the severity of organ dysfunction and inflammatory response during APMP in the experiment.
Publisher
LLC Science and Innovations
Reference17 articles.
1. Karyampudi A, Nabi Z, Reddy DN. Risk factors and prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: An update. EMJ. 2021; 6 (4): 96-108.
2. Akshintala VS, Goenka MK, Kamal A, et al. Sa1386 risk factors for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in high-risk patients: Secondary analysis of a randomized controlled study. GIE. 2017; 85 (5): AB219-20. DOI: 10.1016/j.gie. 2017.03.489
3. Cahyadi O, Tehami N, de-Madaria E, Siau K. Post-ERCP pancreatitis: Prevention, diagnosis and management. Medicina (MDPI). 2022; 58 (9): 1261. DOI: 10.3390/medicina58091261
4. Lin Y, Liu X, Cao D.-Q, et al. Analysis of risk factors and prevention strategies of post-ERCP pancreatitis. Eur Rev Med Pharmacol Sci. 2017; 21 (22): 5185-90. DOI: 10.26355/eur-rev_201711_13838
5. Dubravcsik Z, Hritz I, Szepes A, et al. Risk factors of post-ERCP pancreatitis in high-risk patients despite prevention with prophylactic pancreatic stents. Scand J Gastroenterol. 2020; 55(1): 95-9. DOI: 10.1080/00365521.2019.1701069